Erectile dysfunction (ED) is a prevalent medical condition affecting 18 million men and their sexual partners in the United States alone. In the majority of patients, ED is related to alterations in the flow of blood to or from the penis. Undeniably, significant progress has been made in understanding the multifactorial mechanisms that modulate erectile capacity and predispose one to ED, and this, in turn, has led to the availability of more effective treatment options. Nonetheless, all current therapies have untoward side effects, and moreover, there are still no satisfactory treatments for many patients with ED. Further enhancements in the treatment of ED would logically result from both early intervention and more detailed mechanistic insight into the characteristics of the disease process per se. This fact underscores the importance of improved understanding of the initiation, development and progression of ED. However, to do so requires longitudinal studies on animal models that more closely approximate the corresponding clinical features and time course of human disease. The goal of this report is twofold. First, to provide a brief general overview of the applicability of commonly used animal models for the study of ED. The second and primary goal is to highlight the scientific rationale for using non-human primates to evaluate the impact of atherosclerosis-induced vascular disease on the penile and systemic circulatory systems. This latter goal seems especially relevant in light of the recent literature documenting a link between ED and systemic vascular disease, a finding that has major implications in an aging US male population consuming a high fat diet. Keywords: animal models; atherosclerosis; non-human primates; vascular disease INTRODUCTION Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance.1 --4 ED often has profound effects on intimate relationships, quality of life and overall self-esteem, causing serious distress and prompting men to seek medical attention. The economic impact of ED is multifaceted, with direct costs that include physician evaluation, pharmacotherapy and diagnostic testing, and indirect costs that include lost time at work, lost productivity and effects on the man's partner, family and coworkers. The Massachusetts Male Aging Study indicates that the prevalence of ED increases sharply with age. ED of some degree of severity is observed in 39% of men aged 40 years and in 67% of men aged 70 years.